Spinal Muscular Atrophy Clinical Trial
— CHERISHOfficial title:
A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy
Verified date | February 2021 |
Source | Biogen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally to participants with later-onset Spinal Muscular Atrophy (SMA). The secondary objective is to examine the safety and tolerability of nusinersen administered intrathecally to participants with later-onset SMA.
Status | Completed |
Enrollment | 126 |
Est. completion date | February 20, 2017 |
Est. primary completion date | February 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 12 Years |
Eligibility | Key Inclusion Criteria: - Parent or guardian has signed informed consent and, if indicated per participant's age and institutional guidelines, participant has signed informed assent - Be medically diagnosed with Spinal Muscular Atrophy (SMA) - Have onset of clinical signs and symptoms consistent with SMA at greater than 6 months of age - Be able to sit independently, but has never had the ability to walk independently - Have Motor Function Score (Hammersmith Functional Motor Scale - Expanded) greater than or equal to 10 and less than or equal to 54 at Screening - Be able to complete all study procedures, measurements and visits and parent or guardian and subject has adequately supportive psychosocial circumstances, in the opinion of the Investigator - Have an estimated life expectancy of greater than 2 years from Screening, in the opinion of the Investigator - Meet age-appropriate institutional criteria for use of anesthesia and sedation, if use is planned for study procedures - For subjects who have reached reproductive maturity, satisfy study contraceptive requirements Key Exclusion Criteria: - Respiratory insufficiency, defined by the medical necessity for invasive or non-invasive ventilation for greater than 6 hours during a 24 hour period, at Screening - Medical necessity for a gastric feeding tube, where the majority of feeds are given by this route, as assessed by the Site Investigator - Severe contractures or severe scoliosis evident on X-ray examination at Screening - Hospitalization for surgery (i.e., scoliosis surgery, other surgery), pulmonary event, or nutritional support within 2 months of Screening or planned during the duration of the study - Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period - History of brain or spinal cord disease, including tumors, or abnormalities by magnetic resonance imaging (MRI) or computed tomography (CT) that would interfere with the LP procedures or cerebrospinal fluid (CSF) circulation - Presence of an implanted shunt for the drainage of CSF or an implanted central nervous system (CNS) catheter - History of bacterial meningitis - Dosing with IONIS-SMN Rx in any previous clinical study - Prior injury (e.g., upper or lower limb fracture) or surgical procedure which impacts the subject's ability to perform any of the outcome measure testing required in the protocol and from which the subject has not fully recovered or achieved a stable baseline - Clinically significant abnormalities in hematology or clinical chemistry parameters or electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit that would render the subject unsuitable for inclusion - Treatment with another investigational drug (e.g., oral albuterol or salbutamol, riluzole, carnitine, creatine, sodium phenylbutyrate, et.c), biological agent, or device within 1-month of Screening or 5 half-lives of study agent, whichever is longer. Treatment with valproate or hydroxyurea within 3-months of Screening. Any history of gene therapy, antisense oligonucleotide therapy, or cell transplantation. - Ongoing medical condition that according to the Site Investigator would interfere with the conduct and assessments of the study. Examples are medical disability (e.g., wasting or cachexia, severe anemia, etc.) that would interfere with the assessment of safety or would compromise the ability of the subject to undergo study procedures. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Canada | Children's Hospital - London Health Sciences Centre | London | Ontario |
Canada | McGill University Health Centre-Glen Site-CIM | Montreal | Quebec |
France | Armand Trousseau Hospital, I-Motion, Clinical Trials Platform | Paris | |
Germany | Universitatsklinikum Essen | Essen | |
Germany | University Hospital Freiberg, Center for Paediatrics and Adolescent Medicine, Department of Neuropaediatrics and Muscular Disease | Freiburg | |
Hong Kong | The University of Hong Kong, Queen Mary Hospital, Department of Paediatrics and Adolescent Medicine | Hong Kong | Hong Kong SAR |
Italy | AOU Policlinico G. Martino Dipartimento di Neuroscienze e Centro Clinico Nemo Sud | Messina | |
Italy | Fondazione Policlinico Universitario Agostino Gemelli-Universita Cattolica de Sacro Cuore-UOC Neuropsichiatre Infantile | Rome | |
Japan | Hyogo College of Medicine | Nishinomya-shi | Hyogo |
Japan | Tokyo Women's Medical University | Shinjuku-ku | Tokyo |
Korea, Republic of | Seoul National University Children's Hospital | Seoul | Korea |
Spain | Hospital Sant Joan de Deu | Barcelona | |
Sweden | University of Gothenburg, The Queen Silvia Children's Hospital | Gothenburg | |
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Ann and Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois |
United States | Children's Medical Center | Dallas | Texas |
United States | UCLA Clinical and Translational Research Center | Los Angeles | California |
United States | Columbia University Medical Center | New York | New York |
United States | Nemours Children's Hospital | Orlando | Florida |
United States | Lucile Packard Children's Hospital at Stanford | Palo Alto | California |
United States | Children's Hospital of Philadelphia - Neurology | Philadelphia | Pennsylvania |
United States | Oregon Health & Science University | Portland | Oregon |
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Biogen |
United States, Canada, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Spain, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 | The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. The scale was originally developed with 20 scored activities and was devised for use in children with SMA Type 2 and Type 3 with limited ambulation to give objective information on motor ability and clinical progression. The expanded scale includes an additional module of 13 items developed to allow for evaluation of ambulatory SMA patients. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0=being unable, 1=performed with some compensation, and 2=unaided. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. | Baseline and Month 15 | |
Secondary | Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score at Month 15 | The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. The scale was originally developed with 20 scored activities and was devised for use in children with SMA Type 2 and Type 3 with limited ambulation to give objective information on motor ability and clinical progression. The expanded scale includes an additional module of 13 items developed to allow for evaluation of ambulatory SMA patients. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0=being unable, 1=performed with some compensation, and 2=unaided. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. | Baseline and Month 15 | |
Secondary | Proportion of Participants That Achieved Any New Motor Milestone at Month 15 | New motor milestones are defined as sitting without support, hands-and-knees crawling, standing with assistance, walking with assistance, standing alone and walking alone. | Month 15 | |
Secondary | Number of New Motor Milestones Achieved Per Participant | New motor milestones are defined as sitting without support, hands-and-knees crawling, standing with assistance, walking with assistance, standing alone and walking alone. | Month 15 | |
Secondary | Change From Baseline in Revised Upper Limb Module (RULM) Test | The RULM Test is used in patients with SMA to assess upper limb functional ability items that are reflective of activities of daily living (i.e., raise a can to mouth as if drinking, take a coin and place it in a box, remove the lid of a container). The RULM test has a total of 20 items with an entry item that serves as functional class identification and does not contribute to the total score. The remaining 19 scorable items reflect different functional domains and are graded on a 3-point system with a score of 0 (unable), 1 (able, with modification), and a maximum of 2 (able, no difficulty). There is only 1 item (item I) that is scored as a can/cannot score, with 1 as the highest score. Scorable items are summed for a total score range of 0-37, with higher scores increased great upper limb function. A positive change from Baseline indicates improvement. | Baseline and Month 15 | |
Secondary | Proportion of Participants That Achieved Standing Alone | If the participant was unable to achieve standing alone at Baseline but could achieve this at Month 15 then they were considered a responder. If they could not achieve this or if a participant terminated the study prior to the 15-month assessment due to treatment failure or death, then any imputed value was ignored and the participant was considered as a non-responder. | Month 15 | |
Secondary | Proportion of Participants That Achieved Walking With Assistance | If the participant was unable to achieve walking with assistance at baseline but could achieve this at Month 15 then they were considered a responder. If they could not achieve this or if a participant terminated the study prior to the 15-month assessment due to treatment failure or death, then any imputed value was ignored and the participant was considered as a non-responder. | Month 15 | |
Secondary | Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs: any sign, symptom, or diagnosis/disease that is unfavorable or unintended, that is new, or if pre-existing, worsens in participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. SAEs: an event that results in death; an event that, in the view of the investigator, places the participant at immediate risk of death; an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a participant; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity. Any other medically important event that, in the opinion of the investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. | Baseline through Month 15 | |
Secondary | Number of Participants With Clinically Significant Vital Sign Abnormalities | Vital signs assessed for clinical significance include resting blood pressure, pulse, respiratory rate, and temperature. | Baseline through Month 15 | |
Secondary | Number of Participants With Clinically Significant Weight Abnormalities | Weight changes assessed from Baseline to Month 15. | Baseline through Month 15 | |
Secondary | Number of Participants With Clinically Significant Neurological Examination Abnormalities | Neurological changes assessed for clinical significance include assessment of mental status, level of consciousness, sensory function, motor function, cranial nerve function, and reflexes. | Baseline through Month 15 | |
Secondary | Number of Participants With Clinically Significant Physical Examination Abnormalities | Physical examination changes were assessed for clinical significance. | Baseline through Month 15 | |
Secondary | Number of Participants With Clinically Significant Laboratory Parameter Abnormalities | Laboratory parameter changes assessed for clinical significance include serum chemistry, hematology, coagulation and urinalysis. | Baseline through Month 15 | |
Secondary | Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results | The number of participants with abnormal, clinically relevant worsening, defined as participants with an ECG interpreted as abnormal and clinically relevant, with a comparison with Baseline value is reported. | Baseline through Month 15 | |
Secondary | Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure | Concomitant medications include prescription and over-the-counter medications administered to participants on or after the first day of study treatment. | Baseline through Month 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04851873 -
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
|
Phase 3 | |
Completed |
NCT03223051 -
Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Recruiting |
NCT05794139 -
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Completed |
NCT02003937 -
Aerobic Training in Patients With Spinal Muscular Atrophy Type III
|
N/A | |
Not yet recruiting |
NCT00961103 -
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)
|
N/A | |
Completed |
NCT00227266 -
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
Completed |
NCT00374075 -
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
|
Phase 1 | |
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Recruiting |
NCT05779956 -
Personalized Medicine for SMA: a Translational Project
|
||
Recruiting |
NCT03300869 -
Natural History of Types 2 and 3 SMA in Taiwan
|
||
Recruiting |
NCT03217578 -
Neonatal Spinal Muscular Atrophy (SMA) Screening
|
||
Completed |
NCT01703988 -
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02235090 -
Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting
|
N/A | |
Completed |
NCT02123186 -
Newborn Screening for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00756821 -
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00004771 -
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
|
Phase 2 | |
Recruiting |
NCT05366465 -
Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
|
||
Recruiting |
NCT06310421 -
Spinal Muscular Atrophy Neonatal Screening Program
|